Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
OBJECTIVE: As uncontrolled hyperuricemia has been associated with an increased risk of cardiovascular disease and the progression of chronic kidney disease (CKD), management of serum uric acid levels is important. The aim of this study was to evaluate the effectiveness of febuxostat in regulating uncontrolled hyperuricemia in patients with renal dysfunction.
MATERIALS AND METHODS: We included patients with CKD and persistent uncontrolled hyperuricemia despite treatment with allopurinol. The primary outcome of the study, which was the overall response rate of febuxostat, was defined as the proportion of patients that achieved a serum uric acid level < 7.0 mg/dL. The secondary outcomes included the change in renal function and factors that might influence treatment outcomes. The safety outcome was evaluated based on the incidence of adverse reactions.
RESULTS: A total of 111 patients who switched medication to febuxostat were included. Febuxostat treatment significantly lowered serum uric acid level and the response rates were above 70% at all the time points for 1 year. Febuxostat-treated patients demonstrated no significant change in renal function during the study period. A history of gout attack decreased the response rate of febuxostat (odds ratio (OR): 3.13, 95% confidence interval (CI): 1.08 - 9.06), whereas low-dose aspirin use significantly increased response rate (OR: 0.29, 95% CI: 0.09 - 0.92) in the first month. No patients experienced any severe adverse events.
CONCLUSIONS: Febuxostat effectively lowered serum uric acid levels and was well tolerated in patients with CKD and allopurinol-refractory hyperuricemia.
.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
International journal of clinical pharmacology and therapeutics - 56(2018), 7 vom: 11. Juli, Seite 321-327 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kwak, Chae Hee [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
101V0R1N2E |
|---|
| Anmerkungen: |
Date Completed 27.08.2018 Date Revised 27.08.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.5414/CP202735 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM283973803 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM283973803 | ||
| 003 | DE-627 | ||
| 005 | 20231225042134.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5414/CP202735 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0946.xml |
| 035 | |a (DE-627)NLM283973803 | ||
| 035 | |a (NLM)29750634 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kwak, Chae Hee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.08.2018 | ||
| 500 | |a Date Revised 27.08.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: As uncontrolled hyperuricemia has been associated with an increased risk of cardiovascular disease and the progression of chronic kidney disease (CKD), management of serum uric acid levels is important. The aim of this study was to evaluate the effectiveness of febuxostat in regulating uncontrolled hyperuricemia in patients with renal dysfunction | ||
| 520 | |a MATERIALS AND METHODS: We included patients with CKD and persistent uncontrolled hyperuricemia despite treatment with allopurinol. The primary outcome of the study, which was the overall response rate of febuxostat, was defined as the proportion of patients that achieved a serum uric acid level < 7.0 mg/dL. The secondary outcomes included the change in renal function and factors that might influence treatment outcomes. The safety outcome was evaluated based on the incidence of adverse reactions | ||
| 520 | |a RESULTS: A total of 111 patients who switched medication to febuxostat were included. Febuxostat treatment significantly lowered serum uric acid level and the response rates were above 70% at all the time points for 1 year. Febuxostat-treated patients demonstrated no significant change in renal function during the study period. A history of gout attack decreased the response rate of febuxostat (odds ratio (OR): 3.13, 95% confidence interval (CI): 1.08 - 9.06), whereas low-dose aspirin use significantly increased response rate (OR: 0.29, 95% CI: 0.09 - 0.92) in the first month. No patients experienced any severe adverse events | ||
| 520 | |a CONCLUSIONS: Febuxostat effectively lowered serum uric acid levels and was well tolerated in patients with CKD and allopurinol-refractory hyperuricemia. | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Gout Suppressants |2 NLM | |
| 650 | 7 | |a Febuxostat |2 NLM | |
| 650 | 7 | |a 101V0R1N2E |2 NLM | |
| 650 | 7 | |a Uric Acid |2 NLM | |
| 650 | 7 | |a 268B43MJ25 |2 NLM | |
| 650 | 7 | |a Allopurinol |2 NLM | |
| 650 | 7 | |a 63CZ7GJN5I |2 NLM | |
| 700 | 1 | |a Sohn, Minji |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Nayoung |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Yoon-Sook |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Yon Su |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Jung Mi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical pharmacology and therapeutics |d 1997 |g 56(2018), 7 vom: 11. Juli, Seite 321-327 |w (DE-627)NLM075091739 |x 0946-1965 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2018 |g number:7 |g day:11 |g month:07 |g pages:321-327 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5414/CP202735 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2018 |e 7 |b 11 |c 07 |h 321-327 | ||